Varenicline for Smoking Cessation in Pancreatitis

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07874841
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Varenicline (VAR) — DRUG
    Varenicline is the treatment being offered in this treatment. Treatment will entail oral varenicline 1 mg twice a day (BID) for a total of 12 weeks. Initial titration begins in the following manner: * Days 1-3: 0.5 mg once daily * Days 4-7: 0.5 mg twice daily * Day 8 through end of treatment (12 weeks): 1 mg twice daily

Study Details

This study will look at how safe and how effective varenicline, a commonly used medication for smoking cessation, is in helping patients with pancreatitis stop smoking cigarettes. Individuals who agree to be part of the study will be treated with varenicline for 12 weeks, after which we will see how many have stopped smoking.

Key Dates

First listed
Oct 15, 2026
Start date
Nov 13, 2026
Status verified
Oct 2026
Primary completion
Nov 1, 2028
Completion
Nov 1, 2029

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Varenicline treatment
    All participants in this arm will receive standard dosing of oral varenicline for 12 weeks. Dosing entails the following: * Days 1-3: 0.5 mg once daily * Days 4-7: 0.5 mg twice daily * Day 8 through end of treatment (12 weeks): 1 mg twice daily

Primary Outcome Measure

Smoking Cessation [ Time Frame: 12-weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Luis Ospina Velasquez
[email protected]
507-538-1827
Samuel Han (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies